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Abstract
Background: Mass spectrometry-based protein identification is a very challenging task. The main identification
approaches include de novo sequencing and database searching. Both approaches have shortcomings, so an
integrative approach has been developed. The integrative approach firstly infers partial peptide sequences, known
as tags, directly from tandem spectra through de novo sequencing, and then puts these sequences into a
database search to see if a close peptide match can be found. However the current implementation of this
integrative approach has several limitations. Firstly, simplistic de novo sequencing is applied and only very short
sequence tags are used. Secondly, most integrative methods apply an algorithm similar to BLAST to search for
exact sequence matches and do not accommodate sequence errors well. Thirdly, by applying these methods the
integrated de novo sequencing makes a limited contribution to the scoring model which is still largely based on
database searching.
Results: We have developed a new integrative protein identification method which can integrate de novo
sequencing more efficiently into database searching. Evaluated on large real datasets, our method outperforms
popular identification methods.
Background
Mass spectrometry (MS) is a commonly used, high-
throughput tool for studying proteins. The procedure of
MS-based protein identification involves digesting pro-
teins into peptides, which are then separated, fragmented,
ionised, and captured by mass spectrometers. Proteins
are finally identified from the peaks of the captured mass
spectra using computational methods, where each peak
theoretically represents a peptide fragment ion. However
accurate identification of proteins from tandem mass
spectra is a very challenging task and existing methods
can typically identify fewer than 50% of the proteins in a
complex sample [1-3]. Therefore, there is a critical need
for new protein identification methods that can improve
the identification accuracy and reliability.
Existing protein identification methods can be cate-
gorised into 2 approaches: the database search approach
and the de novo sequencing approach. The database
search approach has been widely used and is more popu-
lar. It identifies proteins by generating theoretical spectra
in silico from a given protein sequence database and
comparing experimental spectra with the theoretical ones
to find the closest matches. A number of methods have
been developed, for example SEQUEST [4] which applies
a cross correlation scoring model, X!Tandem [5] which
uses a hyper-geometric scoring model, OMSSA [6] which
applies a Poisson scoring model, and MASCOT [7]
which employs a probability-based scoring model.
Despite having the advantage of robustness, the database
search approach has several limitations. It is only effec-
tive if the proteins of interest are already known and the
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utilised database contains the correct protein sequences.
Unfortunately, this is difficult since many studies involve
unknown proteins and protein modifications [8,9].
Therefore, only a portion of the identifications reported
by database search methods is correct. In addition, speci-
fying the enzyme used in the proteolytic digestion can
also exclude the correct peptides from the database
search space and lead to erroneous identifications [10].
The de novo sequencing approach identifies proteins by
extracting protein sequence information directly from the
spectrum peaks derived from peptide fragment ions with-
out recourse to any protein database. Existing de novo
sequencing methods can be classified into two categories.
For the first category, such as Sherenga [11] and Lutefisk
[12], the problem is projected into graph theory and algo-
rithms used for finding the maximum path in a network
topology are applied to achieve identification. In the sec-
ond category, exemplified by PepNovo [13], probability
models for inferring protein sequences from the spectrum
peaks are applied. However, the main idea remains the
same: to find the longest possible peptide sequence that
best matches the experimental spectrum. The de novo
sequencing approach is the only feasible means for finding
novel proteins, detecting amino acid mutations, and so on.
However, de novo sequencing is difficult because tandem
mass spectra are inherently deficient [14]. Even if the opti-
mal path can be obtained, it may not always yield the cor-
rect peptide sequences because peptide fragment ions are
usually under-represented and many intensive peaks in
the spectra may derive from various interferences.
An “intermediate” approach has been proposed to inte-
grate the aforementioned two approaches: short peptide
sequence fragments or “tags” are inferred directly from the
spectrum and a database search is performed to find com-
plete peptide sequences that match the sequence frag-
ments. Thus, the identification process is able to
incorporate information from the two heterogeneous
approaches. This integrative approach has great potential
and several methods have been developed, including
GutenTag [15], Inspect [16], MultiTag [17], etc. These
methods perform favourably compared to existing data-
base search and de novo sequencing methods. However,
current implementation of this integrative approach has
several limitations. Firstly, the utilised de novo sequencing
mechanisms are rather simplistic. Therefore, the inferred
sequence tags are short, and usually consist of 3 amino
acid residues. Such small tags only offer limited informa-
tion and may not significantly improve the accuracy.
When the sample is complex, the errors in these tags may
increase and lead to incorrect identifications [18]. Sec-
ondly, most methods try to find exact sequence matches
of the tags to the database. This undermines the identifica-
tion of new proteins and protein modifications. Even if
methods like MultiTag take a step forward to tolerate a
couple of mismatches, only marginal improvement can be
obtained. Thirdly, existing sequence tag methods still
apply database search-centred scoring models to which de
novo sequencing makes little contribution. With the intro-
duction of high precision ion trap instruments, this leaves
many signal-rich spectra seriously under-utilised.
Therefore, we have developed a new integrative
method, NovoDB, for protein identification. The method
extends the integrative approach introduced by the
sequence tag methods and has several advantages. Firstly,
it incorporates a sophisticated de novo sequencing algo-
rithm and infers the peptide sequences in a data-driven
manner. Much longer sequence tags can be inferred
accurately. Secondly, it does not rely on finding exact
sequence tag matches in the database but employs a
dynamic programming approach to better tolerate
sequencing errors. Thirdly, our method employs a simple
scoring model that gives more weight to the de novo
sequencing. Evaluated on large datasets, generally our
method is able to identify more proteins at the same false
discovery rate (FDR) when compared to 3 popular meth-
ods, including database search-based X!Tandem, de novo
sequencing-based PepNovo, and sequence tag-based
GutenTag.
Methods
Our approach has 5 major stages: (1) spectrum prepro-
cessing, (2) sequence tag inference, (3) sequence tag
query, (4) spectrum ion match, and (5) final scoring. An
overview of the method is given in Figure 1.
Spectrum preprocessing
The first stage is to preprocess the spectra and normalise
the peak intensities. Our method uses two versions of the
peak intensities: the continuous intensities and the discrete
intensities. For each spectrum, the method firstly deter-
mines the baseline intensity and divides each peak’s inten-
sity to the baseline so that a normalised intensity is
obtained. The continuous intensities are used for the ion
matching and the final score calculation, while the discrete
intensities are used for the de novo sequencing-based tag
inference. The normalised peak intensities are discretised
into four levels: no signal, low signal, medium signal, and
strong signal. The method removes the low signal peaks
by using a sliding window mechanism and discards all the
peaks except the top several peaks within each sliding win-
dow. Because different regions of the spectrum have differ-
ent characteristics, our method organises peaks into five
regions based on the mass to charge ratio and utilises this
information in the sequence tag inference.
Sequence tag inference
The second stage is to infer a number of peptide
sequence tags directly from the spectrum. Instead of
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inferring short sequence tags which usually leads to misi-
dentifications [18], NovoDB applies a more sophisticated
algorithm to dynamically infer longer peptide sequences in
a data-driven fashion. This is achieved by incorporating a
hybrid de novo sequencing approach which integrates a
Bayesian Network probability model with a dynamic pro-
gramming algorithm to infer the most probable tags [19].
The sequence tag inference stage consists of 3 major steps
in total.
(1) Spectrum graph construction
Given a preprocessed spectrum S, NovoDB builds the
spectrum graph and connects all edges if the mass differ-
ence between two vertices approximates the residue mass
of an amino acid or other mass offsets of a residue
derived from ion degradations. Since the most intensive
peaks tend to be b- and y-ions, the spectrum graph has
vertices for both interpretations. A vertex for an empty
peptide and a vertex for the intact peptide are also added.
Our method extends the Bayesian Network model used
by PepNovo to calculate the probability of observing
each vertex of the constructed spectrum graph. The
details can be found in [19]. Each vertex of the network
contains a conditional probability table given the values
of its parent vertices. The probability tables are trained
by using the large-scale Seattle dataset [20].
(2) Vertex scoring
Each vertex is scored by comparing one hypothesis that
the peak is a real fragment ion to the other hypothesis
that the match is random. It is calculated by the likeli-
hood ratio:






where Oi represents the score for vertex i, mj is the
mass, S is the spectrum, t is the complete set of all peak
intensities of S, R is the peak region, NT represents the N-
terminal residue’s chemical effect, and CT represents the
C-terminal residue’s chemical effect. Under the hypothesis
that the mass matches are random events, the value of the
denominator in (1), namely Prandom(t|mj, S), can be calcu-
lated as the product of the probabilities of observing
Figure 1 Brief overview of the NovoDB identification method.
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individual peaks at their mass positions. To calculate the
numerator in (1), first assume V is the set of the vertices
in the probability network except the roots, then V = {b+,
y+, b+-H2O, y
2+ ...}. For each vertex v of V, w(v) denotes
the assigned intensities of v’s parents. Preal(tv = i|w(v) = {t1,
t2, ...}) is the probability of detecting intensity i at fragment
ion v given the intensities of its parents. Because vertex v
is independent, the probability of observing ion fragment
intensities of t given that the possible cleavage occurred at




One advantage of the model is that Preal can distin-
guish the likely combinations of ions and ion degrada-
tions from the unlikely combinations.
(3) Sequence tag inference
NovoDB finds several top ranking asymmetric paths as the
most probable peptide sequences. The method employs
the dynamic programming algorithm proposed in [21] to
obtain a set of highly scored peptide sequences by explor-
ing the sub-optimal space from the spectrum graph. There
are two reasons. Firstly, a number of vertices on the opti-
mal path may be false positives because it is common that
many intensive peaks derive from interferences. Secondly,
vertices representing the real fragment ions may not
always have the highest score and thus will not be
included in the optimal path. It is normal that real frag-
ment ions have low intensities or even cannot be detected.
The highly similar segments of the sequences correspond
to the fragment ions that are likely to be correctly identi-
fied, while the ambiguous segments are where the ions are
hardly distinguishable from baseline noise. Given these
characteristics, the most likely peptide sequence tags are
extracted by adapting a dynamic programming-based algo-
rithm similar to ClustalW [22]. In this case, the introduced
“gaps” between the sub-optimal peptide sequences corre-
spond to the ambiguous sections of the tandem mass
spectrum. Thus, it is able to dynamically generate longer
sequence tags than 3 amino acid residues.
Sequence tag query
After sequence tags are obtained, the next stage is to
query a database to see if matches can be found. This is
important firstly because the information provided by the
database can fill the gaps that de novo sequencing leaves
out. Secondly, the sequences directly inferred from the
spectrum may not be sufficient to uniquely identify a
protein. Thirdly, even though the sequences of a novel
protein are not present in the database, homologue pro-
teins may have been discovered and they provide crucial
information for validating and understanding the novel
protein.
Our method applies a sequence similarity search based
on a tailored WU-BLAST algorithm [23]. The algorithm
produces error-tolerant scores and does not require long
and identical sequences to produce a confident protein
hit. The sequence tag query algorithm identifies all high
scoring pairs of regions having high local sequence simila-
rities, namely between an individual peptide’s sequences
in the query and a protein’s sequences from the database.
We have introduced several modifications to the BLOS-
SUM62 matrix to suit the sequence query in the context
of mass spectrometry. Scores for the two pairs of isobaric
amino acid residues: glutamine and lysine, leucine and iso-
leucine, are substituted for their average values. The speci-
ficity of trypsin is considered by reserving the K symbol
for the C-terminal lysine and by introducing a new value
averaged between arginine and lysine to represent a clea-
vage site preceding the peptide sequence. Undefined
amino acid residues are introduced with zero scores in
order to increase the similarity score if peptide sequence
tags are incomplete and contain errors. NovoDB ranks the
reported peptide hits by similarity scores Ss and constrains
the total number of query hits.
Ion matching
The ion matching stage is based on the dot-product
between the observed ions and the theoretical ions gen-
erated in silico from the sequence database. Firstly, each
peptide hit from the database query will be theoretically
fragmented and a vector of peaks P will be created
representing all possible fragment ions. The intensity of
each theoretical peak Pi will be generated using an
empirical fragmentation model similar to SEQUEST. In
total, there will be 9 types of ions to be modelled. The b
+ and y+ ions will be generated having intensities of 100,
while a+ ions will have intensities of 20. The b2+ and y2+
ions will have intensities of 50. The b+-H2O, y
+-H2O,
b+-NH3, and y
+-NH3 ions will all have intensities of 20.
Secondly, experimental peaks will be aligned to theoreti-
cal peaks and the unmatched peaks excluded from the
analysis. The experimental ion series is represented as a
vector I, where the value of Ii corresponds to the inten-
sity of an observed fragment ion or 0 if no fragment ion
is observed. The correlation score Sc is calculated in a
similar way to X!Tandem:




where Nb and Ny represents the number of assigned b-
and y-ions respectively. The ion matching score as given
assumes an underlying hyper-geometric distribution for a
valid match. This model has been shown to be very effec-
tive [24]. The ion matching score is calculated for every
candidate protein returned by the database query.
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Final scoring
The final identification score S is calculated as follows:
S = WdenovoSs ∗ (1 − Wdenovo)Sc,
where Wdenovo represents the weight. The protein with
the highest score is considered to be correct. The delta
score D is also calculated measuring how good the identi-











To evaluate the performance of our method, we use the
raw spectra from two large-scale datasets as a benchmark:
(1) the Aurum dataset [25] and (2) the CPTAC dataset
[26] from Clinical Proteomic Technologies Assessment for
Cancer. The Aurum dataset is generated from a mixture
of 246 known human proteins. The CPTAC dataset
comes from a large-scale study of the reproducibility and
repeatability of the Universal Proteomics Standard Set 1
(UPS1).
Compared methods
We compare NovoDB with 3 other widely used algo-
rithms: (1) the de novo sequencing method PepNovo,
(2) the database search method X!Tandem, and (3) the
sequence tag method GutenTag. PepNovo is one of the
most widely used de novo sequencing methods. X!Tan-
dem has been shown to outperform commercial
SEQUEST and MASCOT database search engines on
some data [27]. GutenTag has been used as a benchmark
for evaluating sequence tag-based methods [17].
Evaluation criteria
We use two different performance criteria. Firstly
we compare the tag inference results of NovoDB with
PepNovo by using the sequence inference accuracy. It is
defined as the ratio of the number of correctly identified
amino acid residues to the total number of identified
residues of a peptide. Secondly, we evaluate how many
peptides can be correctly identified by X!Tandem,
GutenTag, and NovoDB at the same identification FDR.
See Figure 2 for an overview.
Evaluation results
The overall result of the comparison between PepNovo
and NovoDB is given in Figure 3. On average, NovoDB
achieves 10% higher accuracy than PepNovo. As expected,
NovoDB has much better accuracy in identifying longer
peptide sequences. When inferring 5 amino acid residues,
NovoDB achieves slightly better accuracy than PepNovo;
however when inferring 10 residues, NovoDB doubles the
accuracy. This is very important because the length of
sequence tags greatly affects the final identification accu-
racy. Figure 3 demonstrates that both methods can achieve
over 80% accuracy when inferring 3 or 4 residues, while
the accuracy drops to around 60% for NovoDB and 50%
for PepNovo when inferring 9 residues. Therefore, it is
clear that one has to keep a balance: it may become detri-
mental to integrate sequence tags more than 8 residues
long, although in theory it is better to incorporate longer
tags. The comparison results of X!Tandem, GutenTag and
NovoDB are given in Figures 4 and 5. For the Aurum
dataset, X!Tandem marginally outperforms GutenTag.
This may be due to the complicated spectra of the Aurum
dataset. Because only short tags are targeted, it may
become difficult for GutenTag to accurately generate a
series of non-conflicting sequence tags. On the other
hand, the CPTAC dataset was generated on more
advanced instruments, so the spectra have higher mass
accuracy. This enables GutenTag to more accurately infer
short tags. As a result, for a fixed FDR, GutenTag identi-
fies around 12% more peptides than X!Tandem. NovoDB
performs significantly better than both methods. On the
Aurum dataset, NovoDB increases the identification accu-
racy by around 13%, while on the CPTAC dataset NovoDB
correctly identifies around 16% more peptides than X!Tan-
dem at the same FDR. The performance gap between
NovoDB and GutenTag is smaller on the CPTAC dataset.
This shows that integrated de novo sequencing has a
strong effect on the final results especially when spectra
are of good quality. On the other hand, this also indicates
that short sequence tags may not be sufficient when the
sample contains a large number of proteins and the spec-
tra are of higher complexity.
Discussion
Sequences obtained by de novo sequencing are valuable
and can significantly increase identification coverage
when effectively integrated with database searching.
With current fast development of new instruments, this
becomes crucial because the identification coverage of
database search methods cannot be significantly
improved with the increasing resolution of the spectra.
This serious bottleneck may be due to the reliance on
databases, which are seldom complete. On the other
hand, the performance of the de novo sequencing
approach increases proportionally to the increase of the
spectra resolution. In recent years, proteomics research
has shifted from a macro qualitative analysis into a
micro perspective including the study of glycolysis and
phosphoralytion. Unfortunately, database search meth-
ods may lead to misidentifications for these applications
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Figure 2 Overview of the evaluation strategy.
Figure 3 Results of sequence inference accuracy comparison on CPTAC.
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[3,12]. De novo sequencing remains the only feasible
approach in this situation. Therefore, it is essential to
integrate de novo sequencing into database searching.
The evaluation results indicate that one should be care-
ful in choosing the length of peptide sequence tags. Feed-
ing longer tags will facilitate database searching and
potentially increase the identification coverage. However
this may lead to more sequence errors. Existing tag-based
methods choose to use very short sequence tags, e.g. 3
residues long. Such an approach may perform well when
the spectrum has high signal-to-noise ratio or the protein
composition is simple. This explains why GutenTag per-
forms much better on the CPTAC dataset. However,
when the spectra are complicated, it becomes difficult for
this approach to succeed. Therefore, it is critical to dyna-
mically choose a proper sequence tag length based on
each individual spectrum. Results demonstrate that this
may be achieved by exploring the top ranking sub-optimal
solutions of the spectrum graph. Based on our evaluation,
sequence tags of 6 to 7 residues seem to yield the best
results. This should be studied further.
How to effectively integrate de novo sequencing and
database searching into a single scoring model is an open
question. By using existing integrative methods, the
incorporated de novo sequencing algorithm is normally
simplistic and cannot contribute directly to the score
calculation. Given poor quality spectra, this method is
quite reliable. However, such a design cannot efficiently
utilise the high precision and high resolution provided by
the new instruments and may lead to sub-optimal results.
It is therefore important to incorporate a sophisticated de
novo sequencing algorithm and a more global scoring
model that can give de novo sequencing more weight.
Based on our evaluation, when the de novo sequencing
component can directly contribute to the score calcula-
tion, a simple scoring model, as presented by our
NovoDB approach, may work well. In theory, it is very
desirable to incorporate more advanced scoring models
that can integrate more effectively the de novo sequen-
cing component with the database search component. A
more advanced scoring model may further improve the
identification accuracy. However, there is always a trade-
off between the complexity of the scoring model and the
computational cost. Therefore, one has to keep a good
balance between the two when designing new scoring
models. The design of more advanced scoring models is
a very interesting direction for future research.
Conclusions
Protein identification plays a key role in mass spectro-
metry-based protein research. Existing protein identifica-
tion methods have limitations which usually lead to low
Figure 4 Results of peptide identification accuracy comparison on Aurum.
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identification coverage. We have developed a new integra-
tive protein identification method which can integrate de
novo sequencing more efficiently into database searching.
Evaluated on large real datasets, our method outperforms
popular identification methods. This performance demon-
strates that in order to significantly improve the identifica-
tion coverage and accuracy, it may be necessary to
integrate effectively heterogeneous approaches into pro-
tein identification.
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